Sarah Pirrie

Sarah Pirrie serves as a Principal Biostatistician at the Cancer Research UK Clinical Trials Unit within the College of Medical and Dental Sciences at the University of Birmingham. With 42 research outputs and involvement in 14 active projects through 2034, she plays a critical role in advancing cancer clinical trials methodology and statistical analysis.

Her research expertise spans multiple oncology domains:

• Urological cancers (Bladder Cancer, Prostate Cancer)
• Cancer treatment modalities (Chemotherapy, Zoledronic Acid, Strontium-89)
• Survival analysis and clinical outcomes measurement
• Medical imaging applications in cancer staging

Analysis of her recent publications reveals a strong emphasis on optimizing cancer treatment pathways through advanced imaging techniques and innovative clinical trial designs. Her work frequently addresses methodological challenges in comparative effectiveness research, with particular attention to bladder cancer diagnostics and treatment stratification.

Ms. Pirrie serves as a key researcher on major national and international projects including the BladderPath trial, FaR-RMS study for Rhabdomyosarcoma, Thrombo-STOP for lung cancer patients, and the RadIO Trial for bladder cancer treatment. Her statistical expertise has contributed to trial designs that have garnered significant attention in both academic and clinical communities.